Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
about
Buprenorphine Treatment and Patient Use of Health Services after the Affordable Care Act in an Integrated Health Care System.Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement.Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.Perceived barriers to methadone maintenance treatment among Iranian opioid users.
P2860
Q38828787-1FC435E1-83C7-49D2-ADCB-E520763FD762Q39162177-08E636BE-1372-4430-9895-BB9E3302F275Q39200931-5C21DB13-1A10-4B18-AC23-57A6172D54B5Q40207657-100A4EC1-F73B-4786-880D-876DA92589EFQ43823854-D9CC2AA6-9306-4603-839C-0035BC6B66B2Q51579656-7F1B821C-BC46-476E-997A-9409E2EC8CECQ55327370-BC3F3D2C-8136-4F69-A826-C7E7437DD595
P2860
Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@ast
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@en
type
label
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@ast
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@en
prefLabel
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@ast
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@en
P2093
P2860
P1476
Methadone, buprenorphine and p ...... tment: A qualitative analysis.
@en
P2093
Bobbi Jo H Yarborough
Carla A Green
Constance Weisner
Dennis McCarty
Jennifer Mertens
P2860
P304
P356
10.1016/J.DRUGALCDEP.2015.12.031
P577
2016-01-06T00:00:00Z